Taysha Gene Therapies, Inc.TSHANASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank67
3Y CAGR-1.8%
5Y CAGR+22.1%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-1.8%/yr
Annual compound
5Y CAGR
+22.1%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
2.7x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$86.40M+30.9%
2024$66.00M+16.2%
2023$56.78M-37.7%
2022$91.17M-30.9%
2021$131.94M+313.7%
2020$31.89M+3131.3%
2019$987000.00-